Harrow Health Inc. (HROW) experienced a significant post-market plunge of 13.25% on Monday.
The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which revealed earnings that fell significantly short of analyst expectations. Harrow reported Q4 earnings per share of $0.17, missing the FactSet consensus estimate of $0.37 by a wide margin.
Adding to investor concerns, the company issued its 2026 revenue guidance in the range of $350 million to $365 million, which is substantially below the analyst consensus expectation of approximately $386 million to $391 million. This combination of an earnings miss and weaker-than-anticipated forward outlook prompted the post-market selloff.